Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic Review Report; SR0350. 2014 Authors' conclusions CDR found several limitations with the manufacturer's economic analysis. A reanalysis addressing all of these limitations (except treatment waning over time) found that teriflunomide dominated Rebif and Avonex, but the ICUR for teriflunomide versus GA was $409,175. Indexing Status Subject indexing assigned by CRD MeSH Crotonates; Humans; Multiple Sclerosis, Relapsing-Remitting; Toluidines Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000170 Date abstract record published 04/03/2015 |